Literature DB >> 30190945

STAT3 in hepatocellular carcinoma: new perspectives.

Jasmin Svinka1, Wolfgang Mikulits1, Robert Eferl1.   

Abstract

Chronic liver damage and inflammation are strong promoters of hepatocellular carcinoma (HCC) formation. HCC cells communicate with inflammatory and stromal cells via cytokine/chemokine signals. These heterotypic interactions inhibit immunologic anticancer activities and promote protumorigenic activities, such as angiogenesis or invasiveness. STAT3 mediates several reciprocal interactions between liver cancer cells and stromal cells and modulates preconditions of tumor formation such as chronic inflammation. Therefore, activation of STAT3 is considered as a tumor-promoting event in HCC formation. However, the oncogenic role of STAT3 in cancers has been challenged by several reports that suggest a tumor-suppressive activity. Here we discuss tumor-promoting and tumor-suppressive effects of cytokine-activated STAT3 in HCC.

Entities:  

Year:  2013        PMID: 30190945      PMCID: PMC6114013          DOI: 10.2217/hep.13.7

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  112 in total

1.  STAT3 negatively regulates thyroid tumorigenesis.

Authors:  Joana Pinto Couto; Laura Daly; Ana Almeida; Jeffrey A Knauf; James A Fagin; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares; David Lyden; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

2.  Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.

Authors:  Chuanxi Wang; Bao Song; Wei Song; Jie Liu; Aimin Sun; Dehua Wu; Huiming Yu; Jianping Lian; Longhua Chen; Junqing Han
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

3.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

4.  Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice.

Authors:  Norio Horiguchi; Fouad Lafdil; Andrew M Miller; Ogyi Park; Hua Wang; Mohanraj Rajesh; Partha Mukhopadhyay; Xin Yuan Fu; Pal Pacher; Bin Gao
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

5.  Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

Authors:  Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

6.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

7.  STAT3 inhibition of gluconeogenesis is downregulated by SirT1.

Authors:  Yongzhan Nie; Derek M Erion; Zhenglong Yuan; Marcelo Dietrich; Gerald I Shulman; Tamas L Horvath; Qian Gao
Journal:  Nat Cell Biol       Date:  2009-03-22       Impact factor: 28.824

8.  The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Authors:  L Lin; R Amin; G I Gallicano; E Glasgow; W Jogunoori; J M Jessup; M Zasloff; J L Marshall; K Shetty; L Johnson; L Mishra; A R He
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

9.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Authors:  Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S Kim; Magaly Zappa; Silvana Lanzalone; Xun Lin; Samuel Deprimo; Charles Harmon; Ana Ruiz-Garcia; Maria J Lechuga; Ann Lii Cheng
Journal:  Lancet Oncol       Date:  2009-07-06       Impact factor: 41.316

Review 10.  Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.

Authors:  Monica Marra; Ignazio M Sordelli; Angela Lombardi; Monica Lamberti; Luciano Tarantino; Aldo Giudice; Paola Stiuso; Alberto Abbruzzese; Rossella Sperlongano; Marina Accardo; Massimo Agresti; Michele Caraglia; Pasquale Sperlongano
Journal:  J Transl Med       Date:  2011-10-10       Impact factor: 5.531

View more
  12 in total

1.  Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3.

Authors:  Xiaoyun Dai; Kwang Seok Ahn; Chulwon Kim; Kodappully Sivaraman Siveen; Tina H Ong; Muthu K Shanmugam; Feng Li; Jizhong Shi; Alan Prem Kumar; Ling Zhi Wang; Boon Cher Goh; Junji Magae; Kam M Hui; Gautam Sethi
Journal:  Mol Oncol       Date:  2015-01-05       Impact factor: 6.603

2.  Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction.

Authors:  Yongfa Zheng; Pingpo Ming; Chengliang Zhu; Yu Si; Shilei Xu; Aidong Chen; Jun Wang; Binghong Zhang
Journal:  J Biol Chem       Date:  2019-01-18       Impact factor: 5.157

Review 3.  Current strategies and progress for targeting the "undruggable" transcription factors.

Authors:  Jing-Jing Zhuang; Qian Liu; Da-Lei Wu; Lu Tie
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

4.  Traditional Chinese Medicine Xiaoai Jiedu Recipe Suppresses the Development of Hepatocellular Carcinoma via Regulating the microRNA-29a/Signal Transducer and Activator of Transcription 3 Axis.

Authors:  Yanfen Shi; Wuming Kong; Yanxu Lu; Yu Zheng
Journal:  Onco Targets Ther       Date:  2020-07-29       Impact factor: 4.147

5.  Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2.

Authors:  Ji-Sook Jeon; Sora Kwon; Kiwon Ban; Young- Kwon Hong; Curie Ahn; Jung-Suk Sung; Inho Choi
Journal:  Nutr Cancer       Date:  2019-01-19       Impact factor: 2.900

6.  Regulation of signal transducer and activator of transcription 3 activation by dual-specificity phosphatase 3.

Authors:  Ba Reum Kim; Jain Ha; Eunjeong Kang; Sayeon Cho
Journal:  BMB Rep       Date:  2020-06       Impact factor: 4.778

Review 7.  Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches.

Authors:  Zahra Farzaneh; Massoud Vosough; Tarun Agarwal; Maryam Farzaneh
Journal:  Cancer Cell Int       Date:  2021-04-13       Impact factor: 5.722

Review 8.  High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway.

Authors:  Hyuk Moon; Kyungjoo Cho; Sunyeong Shin; Do Young Kim; Kwang-Hyub Han; Simon Weonsang Ro
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

9.  Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression.

Authors:  Yucel Aydin; Ramazan Kurt; Kyoungsub Song; Dong Lin; Hanadi Osman; Brady Youngquist; John W Scott; Nathan J Shores; Paul Thevenot; Ari Cohen; Srikanta Dash
Journal:  Cancers (Basel)       Date:  2019-09-20       Impact factor: 6.639

10.  3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma.

Authors:  Chakrabhavi Dhananjaya Mohan; Min Hee Yang; Shobith Rangappa; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Tahani Awad Alahmadi; Amudha Deivasigamani; Kam Man Hui; Gautam Sethi; Kanchugarakoppal S Rangappa; Kwang Seok Ahn
Journal:  Biology (Basel)       Date:  2021-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.